04- Cholinergics Flashcards
(49 cards)
atropine
cholinergic antagonist that is MUSCARINIC selective
- no selectivity for Muscarinic sub-types
- tertiary amine so easily cross BBB and cause CNS toxicity
- quickly distributed after administration (30-60 min in CNS)
- duration of action 5-10 hours
- most sensitive tissues are salivary, bronchial, and sweat glands
- has LONG-acting topical application used in eyes that elicits mydriasis and cycloplegia, relieves urinary incontinence, may be useful adjunct therapy for Parkinsonism, overcome poisoning by O-P or muscarine mushrooms, and can inhibit some vagal slowing of heart due to MI
homatropine
cholinergic antagonist that is MUSCARINIC selective
- tertiary amine so can cross BBB (mainly used topically so this does not normally occur)
- duration of action 2-4 hours
- has INTERMEDIATE-acting topical application that is useful for eliciting mydriasis and cycloplegia (for eye exams)
scopolamine
cholinergic antagonist that is MUSCARINIC selective
- quickly distributed after admin (30-60 min in CNS)
- duration of action 5-10 hours
- tertiary amine derivative primarily used for CNS effects (CNS depression manifested with drowsiness, amnesia, fatigue, dreamless sleep)
- most effective treatment for motion sickness
- side effects include sedation and dry mouth
methscopolamine (Pamine)
cholinergic antagonist that is MUSCARINIC selective
- duration of action 5-10 hours
- quaternary derivative of scopolamine so only used in PNS and lacks CNS effects
- primarily used for GI diseases
trihexyphenidyl (Artane)
cholinergic antagonist that is MUSCARINIC selective
- tertiary amine that readily crosses BBB and can cause CNS toxicity
- duration of action 3-6 hours
- useful adjunct therapy to dec. uncoordinated movement and excess salivation for Parkinsonism (main use) and extra-pyramidal side effects of anti-psychotics
cyclopentolate (Cyclogyl)
cholinergic antagonist that is MUSCARINIC selective
- short acting (3-6hrs) topical application to induce mydriasis and cycloplegia
- non-specific muscarinic blocker so can exhibit all associated effects of muscarinic blockade
ipratroprium (Atrovent)
cholinergic antagonist that is MUSCARINIC selective
- aerosol, synthetic analog of atropine
- quaternary derivative of atropine
- bronchodilation, tachycardia, decreased salivation
- minimizes mucociliary clearance effect and is useful for patients with airway problems (maintains airway fluidity)
- specifically targeted when used as an inhalant and unable to cross membranes (so will only bronchodilate)
- used for patients with COPD
tiotropium (Spiriva)
cholinergic antagonist that is MUSCARINIC selective
- synthetic analog of atropine
- serves as LONGER ACTING “topical” inhalation application that targets bronchodilation and specifically minimizes mucociliary clearance problems (maintains airway fluidity)
darifenacin (Enablex)
cholinergic antagonist that is M3 selective
- slows micturition
- aids in treatment of urinary urgency due to inflammatory bladder problems
- may alleviate bladder spasm following urologic surgery
- may precipitate urinary retention in men with prostatic hyperplasia
solifenacin (VESIcare)
cholinergic antagonist that is M3 selective
- slows micturition
- aids in treatment of urinary urgency due to inflammatory bladder problems
- may alleviate bladder spasm following urologic surgery
- may precipitate urinary retention in men with prostatic hyperplasia
tolterodine (Detrol)
cholinergic antagonist that is M3 selective
- slows micturition
- aids in treatment of urinary urgency due to inflammatory bladder problems
- may alleviate bladder spasm following urologic surgery
- may precipitate urinary retention in men with prostatic hyperplasia
mecamylamine (Inversine)
cholinergic antagonist that is NICOTINIC selective
- acts as non-depolarizing competitive antagonist
- secondary amine developed to improve absorption from GI tract following oral administration
- Duration of action: 12 hours
- CNS side effects include tremors, confusion, seizures, mania, depression
trimethaphan (Arfonad)
cholinergic antagonist that is NICOTINIC selective
- acts as non-depolarizing competitive antagonist
- sulfonium (positively charged sulfur group) developed for IV use (lasts minutes)
- used during surgery to minimize blood loss in OR
- monitor carefully for excessive hypotension and brain anoxia
succinylcholine
- cholinergic antagonist that is DEPOLARIZING
- non-competitive receptor agonist that opens Na+ channels and mimics effect of ACh
- not substrate for AChE, but activity short because broken down by plasma cholinesterase
- only depolarizing NM blocker
- Phase I block (depolarizing): membrane remains depolarized and unresponsive inducing flaccid paralysis
- Phase II block (desensitizing): membrane repolarizes but receptor is desensitized due to prolonged exposure to Succ.
- cannot reverse action of succinylcholine***
curare (d-tubocurarine)
cholinergic antagonist that is NON-DEPOLARIZING
- LONG-acting benzylisoquinoline that competes with ACh for binding to N2 receptor sites which prevents depolarization of membrane and flaccid paralysis
- devoid of vagolytic and ganglionic blocking activity
- may elicit some histamine release
- poor lipid solubility so cannot cross BBB
- can be reversed by AChE inhibitor which leads to more ACh at synapse which can compete off antagonist from receptor
atracurium (Tracrium)
cholinergic antagonist that is NON-DEPOLARIZING
- competes with ACh for binding to N2 receptor sites which prevents depolarization of membrane and flaccid paralysis
- poor lipid solubility so cannot cross BBB
- can be reversed by AChE inhibitor which leads to more ACh at synapse which can compete off antagonist from receptor
cisatracurium (Nimbex)
cholinergic antagonist that is NON-DEPOLARIZING
- INTERMEDIATE-acting benzylisoquinoline that competes with ACh for binding to N2 receptor sites which prevents depolarization of membrane and flaccid paralysis
- devoid of vagolytic and ganglionic blocking activity
- may elicit some histamine release
- poor lipid solubility so cannot cross BBB
- can be reversed by AChE inhibitor which leads to more ACh at synapse which can compete off antagonist from receptor
mivacurium (Mivacron)
cholinergic antagonist that is NON-DEPOLARIZING
- SHORT-acting benzylisoquinoline that competes with ACh for binding to N2 receptor sites which prevents depolarization of membrane and flaccid paralysis
- devoid of vagolytic and ganglionic blocking activity
- may elicit some histamine release
- poor lipid solubility so cannot cross BBB
- can be reversed by AChE inhibitor which leads to more ACh at synapse which can compete off antagonist from receptor
pancuronium (Pavulon)
cholinergic antagonist that is NON-DEPOLARIZING
- LONG-acting ammonio steroid that causes neuromuscular blockade by competing with ACh for binding to N2 receptor sites which prevents depolarization of membrane and flaccid paralysis
- will have some muscarinic block leading to vagal blockade and tachycardia
- poor lipid solubility so cannot cross BBB
- can be reversed by AChE inhibitor which leads to more ACh which can compete off antagonist from receptor
vecuronium (Norcuron)
cholinergic antagonist that is NON-DEPOLARIZING
- INTERMEDIATE-acting ammonio steroid that causes neuromuscular blockade by competing with ACh for binding to N2 receptor sites which prevents depolarization of membrane and flaccid paralysis
- will have some muscarinic block leading to vagal blockade and tachycardia
- poor lipid solubility so cannot cross BBB
- can be reversed by AChE inhibitor which leads to more ACh which can compete off antagonist from receptor
Cholinergic Antagonists
block the effects of ACh and ACh-like agonists from interacting with the various nicotinic and muscarinic receptors and prevent the normal physiological responses caused by these receptors
Anti-Muscarinic (parasympatholytics) Agents
anticholinergic drugs that combine with muscarinic receptors (M1-M3) and prevent physiologic responses to ACh at post-ganglionic parasympathetic transmission sites
- used when both mydriasis and cycloplegia are required
- block vagal slowing of the heart due to antagonism of muscarinic receptors on SA and AV nodes
- elicit bronchodilation and decreased secretions in airway
- decrease smooth muscle motility and secretions in GI tract
- decrease activity of salivary glands and thermoregulatory sweat glands
- relax smooth muscle of genitourinary system
- have anti-parkinson, anti-motion sickness and amnesic properties
Anti-Nicotinic Agents
anticholinergic agents that block nicotinic receptors
- ganglionic blockers (N1)
- NMJ blockers (N2)
Tertiary Amine
nitrogen forming 3 bonds and has a neutral charge
-derivatives can cross mucous membranes and BBB to exert effects on CNS